Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03627767
Recruitment Status : Recruiting
First Posted : August 13, 2018
Last Update Posted : July 16, 2019
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken orally once daily (QD) will be identified and randomized in a double-blind manner to receive 200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible patients will have the option to enter a long-term extension study after completing the initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment.

Condition or disease Intervention/treatment Phase
Dermatitis Dermatitis, Atopic Eczema Skin Diseases Skin Diseases, Genetic Genetic Diseases, Inborn Skin Diseases, Eczematous Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Drug: PF-04965842 100 mg Drug: PF-04965842 200 mg Drug: Placebo Phase 3

Detailed Description:
Responder criteria for randomization at week 12 are defined as a) achieving an IGA of clear (0) or almost clear (1) (on a 5 point scale), b) a reduction from IGA baseline of 2 or more points, and c) reaching an EASI-75 response compared to baseline. Flare requiring rescue treatment is defined as a loss of at least 50% of the EASI response at Week 12 and an IGA score of 2 or higher.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1370 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS
Actual Study Start Date : June 11, 2018
Estimated Primary Completion Date : August 27, 2020
Estimated Study Completion Date : August 27, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: PF-04965842 100 mg QD
Double-blind randomized treatment following open label run-in period.
Drug: PF-04965842 100 mg
PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks

Experimental: PF-04965842 200 mg QD
Double-blind randomized treatment following open label run-in period.
Drug: PF-04965842 200 mg
PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks

Placebo Comparator: Placebo QD
Double-blind randomized treatment following open label run-in period.
Drug: Placebo
Placebo, administered as two tablets to be taken orally once daily for 40 weeks




Primary Outcome Measures :
  1. Loss of response [ Time Frame: Randomization (Week 12) to Week 52 ]
    Loss of response requiring rescue treatment will be evaluated and compared among groups during the blinded treatment period. Loss of response is denoted as flare and is defined as a loss of at least 50% of the Eczema Area and Severity Index (EASI) response at Week 12 and an Investigator's Global Assessment (IGA) score of 2 or higher.


Secondary Outcome Measures :
  1. Investigator's Global Assessment (IGA) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Response based on the IGA at all scheduled time points.

  2. Eczema Area and Severity Index (EASI) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Response based on EASI total score at all scheduled time points.

  3. Pruritus Numberical Rating Scale (NRS) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Response based on at least 4 points improvement in the severity of pruritus NRS from relevant baseline at all scheduled time points. Severity is on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable."

  4. Body Surface Area (BSA) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Change from relevant baseline in percent BSA at all scheduled time points.

  5. SCORing Atopic Dermatitis (SCORAD) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Change from relevant baseline in SCORAD subjective assessments of itch and sleep loss at all scheduled time points. Includes proportion of subjects achieving a >=50% and >=75% improvement in SCORAD (SCORAD-50, SCORAD-75) from relevant baseline at all scheduled time points.

  6. Patient Global Assessment (PtGA) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Change from relevant baseline in PtGA at all scheduled time points.

  7. Dermatology Life Quality Index (DLQI) or Children's DLQI (CDLQI) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Change from relevant baseline in DLQI or CDLQI at all scheduled time points.

  8. Hospital Anxiety Depression Scale (HADS) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Change from relevant baseline in HADS at all scheduled time points. Each question has 0 to 3 scale with 0 being the best "not at all/hardly at all" and 3 being the worst "most of the time/nearly all of the time."

  9. Patient Oriented Eczema Measure (POEM) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Change from relevant baseline in POEM at all scheduled time points.

  10. Pruritus and symptoms Assessment in Atopic Dermatitis (PSAAD) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Change from relevant baseline in the PSAAD at all scheduled time points.

  11. EuroQol Quality of LIfe 5-Dimension 5-Level Scale (EQ-5D-5L) or Youth Scale (EQ-5D-Y) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Change from relevant baseline in EQ-5D-5L or EQ-5D-Y at all scheduled time points.

  12. Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F) or Pediatric FACIT-F (Peds-FACIT-F) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Change from relevant baseline in FACIT-F or Peds-FACIT-F at all scheduled time points.

  13. Short Form-36, acute (SF-36) [ Time Frame: Baseline, Weeks 2, 4, 8, 12, 16, 28, 40, 52 and Rescue Weeks 0, 2, 4, 8, 12, and follow up (defined as 4 weeks post last dose) ]
    Change from relevant baseline in SF-36, acute (adults only) at all scheduled time points.

  14. Investigator's Global Assessment (IGA) [ Time Frame: Randomization (Week 12) to Week 52 ]
    Key Secondary Endpoint: Loss of response based on an IGA score of 2 or higher.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 12 years of age or older with a minimum body weight of 40 kg
  • Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (>= the following scores: BSA10%, IGA 3, EASI 16, Pruritus NRS 4)
  • Recent history of inadequate response or inability to tolerate topical AD treatments or require systemic treatments for AD control

Exclusion Criteria:

  • Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study
  • Prior treatment with JAK inhibitors
  • Other active nonAD inflammatory skin diseases or conditions affecting skin
  • Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
  • Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03627767


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

  Show 258 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT03627767     History of Changes
Other Study ID Numbers: B7451014
JADE REGIMEN ( Other Identifier: Alias Study Number )
2018-000501-23 ( EudraCT Number )
REGIMEN ( Other Identifier: Alias Study Number )
First Posted: August 13, 2018    Key Record Dates
Last Update Posted: July 16, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Pfizer:
atopic dermatitis
atopic eczema
eczema
JAK
janus kinase

Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis
Dermatitis, Atopic
Eczema
Hypersensitivity
Skin Diseases
Genetic Diseases, Inborn
Immune System Diseases
Hypersensitivity, Immediate
Skin Diseases, Genetic
Skin Diseases, Eczematous